The FDA’s review of drug and biological products in this medication class is critical, as a brain impairment impacts between 6.5% and 7.9% of adults in the United States.
Peripheral arterial disease (PAD) describes a phenomenon in which circulation to the leg is diminished due to atherosclerosis, resulting in reduced blood flow and often causing pain that can be limiting to those who experience it.